PS-341
Showing 1 - 25 of 746
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (Bortezomib, Metformin Hydrochloride,
Active, not recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bortezomib
- +2 more
-
Jacksonville, Florida
- +1 more
Jan 5, 2023
Waldenstrom's Macroglobulinemia Trial in Houston (Bortezomib, Rituximab, Valacyclovir)
Active, not recruiting
- Waldenstrom's Macroglobulinemia
- Bortezomib
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Dec 5, 2022
Plasma Cell Myeloma Trial in Rochester (Bortezomib, Daratumumab, Dexamethasone)
Recruiting
- Plasma Cell Myeloma
- Bortezomib
- +3 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 4, 2023
Solid Tumor, Urethral Cancer Trial in Houston (Bortezomib, Gemcitabine, Doxorubicin)
Active, not recruiting
- Solid Tumor
- Urethral Cancer
- Bortezomib
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Sep 22, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Los Angeles (drug, other, biological)
Active, not recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bortezomib
- +4 more
-
Los Angeles, CaliforniaUSC / Norris Comprehensive Cancer Center
Aug 5, 2022
Multiple Myeloma, Refractory Multiple Myeloma Trial (procedure, drug, radiation)
Withdrawn
- Multiple Myeloma
- Refractory Multiple Myeloma
- nonmyeloablative allogeneic hematopoietic stem cell transplantation
- +7 more
- (no location specified)
Jan 4, 2023
Plasma Cell Myeloma Trial in Atlanta (Bortezomib, Daratumumab, Dexamethasone)
Active, not recruiting
- Plasma Cell Myeloma
- Bortezomib
- +3 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Jan 10, 2023
Multiple Myeloma Based on Multi-omics
Enrolling by invitation
- Multiple Myeloma
- Bortezomib
-
Beijing, ChinaBeijng Chao Yang Hospital
Apr 21, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Los Angeles (Bortezomib, Dexamethasone, Pelareorep)
Not yet recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bortezomib
- +3 more
-
Los Angeles, California
- +1 more
Aug 19, 2022
Plasma Cell Myeloma, Renal Failure Trial in Atlanta (Bortezomib, Daratumumab, Dexamethasone)
Recruiting
- Plasma Cell Myeloma
- Renal Failure
- Bortezomib
- +4 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Jun 13, 2022
AL Amyloidosis Trial (procedure, drug, other)
Not yet recruiting
- AL Amyloidosis
- Autologous Hematopoietic Stem Cell Transplantation
- +15 more
- (no location specified)
Aug 28, 2023
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Columbus (Bortezomib, Daratumumab and Hyaluronidase-fihj,
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bortezomib
- +3 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 30, 2021
Waldenstrom's Macroglobulinemia Trial in Boston (Everolimus, Rituximab, Bortezomib)
Terminated
- Waldenstrom's Macroglobulinemia
- Everolimus
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Apr 22, 2021
Myeloma Trial in Little Rock (Melphalan, Velcade, Thalidomide)
Active, not recruiting
- Myeloma
- Melphalan
- +7 more
-
Little Rock, ArkansasUniversity of Arkansas for Medical Sciences
Dec 1, 2021
Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia Trial in Duarte (drug,
Active, not recruiting
- Autologous Hematopoietic Stem Cell Transplant Recipient
- +4 more
- bortezomib
- +7 more
-
Duarte, CaliforniaCity of Hope
Mar 17, 2022
Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia Trial in Houston
Recruiting
- Recurrent Acute Lymphoblastic Leukemia
- +10 more
- Bortezomib
- +8 more
-
Houston, TexasM D Anderson Cancer Center
Sep 21, 2022
Multiple Myeloma Trial in Little Rock (Velcade, Melphalan, Thalidomide)
Active, not recruiting
- Multiple Myeloma
- Velcade
- +7 more
-
Little Rock, ArkansasUniversity of Arkansas for Medical Sciences
Sep 7, 2021
Multiple Myeloma Trial in Chicago (Carfilzomib, Lenalidomide, Dexamethasone)
Recruiting
- Multiple Myeloma
- Carfilzomib
- +3 more
-
Chicago, IllinoisUniversity Of Chicago Medicine Comprehensive Cancer Center
Jun 7, 2021
Mantle Cell Lymphoma Trial in Houston (Bortezomib, Cyclophosphamide, Cytarabine)
Completed
- Mantle Cell Lymphoma
- Bortezomib
- +7 more
-
Houston, TexasM D Anderson Cancer Center
Jan 27, 2022
Acute Lymphoblastic Leukemia Trial in Canada, United States (ITMHA, Dexamethasone, Mitoxantrone)
Active, not recruiting
- Acute Lymphoblastic Leukemia
- ITMHA
- +13 more
-
Los Angeles, California
- +17 more
Jun 6, 2022
Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach
Completed
- Adenocarcinoma of the Gastroesophageal Junction
- +7 more
-
Bronx, New YorkMontefiore Medical Center
Jan 29, 2021
Myeloma Trial in Houston (Trisenox (Arsenic Trioxide), Velcade (Bortezomib), Melphalan)
Completed
- Myeloma
- Trisenox (Arsenic Trioxide)
- +3 more
-
Houston, TexasUT MD Anderson Cancer Center
Sep 1, 2020